ReviewInternational journal of molecular sciences2021
Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Integrated approaches to sensitizing melanoma to radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- A Stretchable, Transparent, Photothermally Stimulated Laser-Induced Graphene Patch for Noninvasive Skin Tumor Treatment.ACS nano · 2026Article
- Is Ultrahigh Dose Rate Critical for the Effectiveness of Microbeam Radiation Therapy in a Broad-Beam Combined Treatment?Advances in radiation oncology · 2026Article
- Review
- New Approaches in Radiotherapy.Cancers · 2025Review
- Application of Synchrotron Radiation in Fundamental Research and Clinical Medicine.Biomedicines · 2025Review
- A 3D Co-Culture Scaffold Approach to Assess Spatially Fractionated Radiotherapy Bystander and Abscopal Immune Effects on Clonogenic Survival.International journal of molecular sciences · 2025Article
- The Combination of Temporal and Spatial Dose Fractionation in Microbeam Radiation Therapy.Biomedicines · 2025Article
- Initial experience of spatially fractionated lattice radiation therapy for palliative treatment of pediatric bulky tumors.Frontiers in oncology · 2025Article
- The Impact of Synchrotron Microbeam Radiation Therapy Combined With Broad Beam in a Preclinical Breast Cancer Model.Advances in radiation oncology · 2025Article
- Superior Anti-Tumor Response After Microbeam and Minibeam Radiation Therapy in a Lung Cancer Mouse Model.Cancers · 2025Article
- Review
- Identification of immune-related genes and integrated analysis of immune-cell infiltration in melanoma.Aging · 2024Article
- Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio.Clinical and translational radiation oncology · 2024Review
- Immune Priming with Spatially Fractionated Radiation Therapy.Current oncology reports · 2023Review
- Increased radiosensitivity of melanoma cells through cold plasma pretreatment mediated by ICG.Journal of radiation research · 2023Article
- In Vitro Effects of Photon Beam and Carbon Ion Radiotherapy on the Perineural Invasion of Two Cell Lines of Neurotropic Tumours.Life (Basel, Switzerland) · 2023Article
- The Synergistic Effect of Cold Atmospheric Plasma Mediated Gold Nanoparticles Conjugated with Indocyanine Green as An Innovative Approach to Cooperation with Radiotherapy.Cell journal · 2023Article
- Targeted Accumulation of Macrophages Induced by Microbeam Irradiation in a Tissue-Dependent Manner.Biomedicines · 2022Article
- Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
Melanoma is the deadliest type of skin cancer, due to its invasiveness and limited treatment efficacy. The main therapy for primary melanoma and solitary organ metastases is wide excision. Adjuvant therapy, such as chemotherapy and targeted therapies are mainly used for disseminated disease. Radiotherapy (RT) is a powerful treatment option used in more than 50% of cancer patients, however, conventional RT alone is unable to eradicate melanoma. Its general radioresistance is attributed to overexpression of repair genes in combination with cascades of biochemical repair mechanisms. A novel sophisticated technique based on synchrotron-generated, spatially fractionated RT, called Microbeam Radiation Therapy (MRT), has been shown to overcome these treatment limitations by allowing increased dose delivery. With MRT, a collimator subdivides the homogeneous radiation field into an array of co-planar, high-dose microbeams that are tens of micrometres wide and spaced a few hundred micrometres apart. Different preclinical models demonstrated that MRT has the potential to completely ablate tumours, or significantly improve tumour control while dramatically reducing normal tissue toxicity. Here, we discuss the role of conventional RT-induced immunity and the potential for MRT to enhance local and systemic anti-tumour immune responses. Comparative gene expression analysis from preclinical tumour models indicated a specific gene signature for an 'MRT-induced immune effect'. This focused review highlights the potential of MRT to overcome the inherent radioresistance of melanoma which could be further enhanced for future clinical use with combined treatment strategies, in particular, immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.